The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 29 of the 36 sources its claims cite were checked for support.
Examining iPSC derived motor neuron variability and genome stability monitoring as a solution
Open accessAbstract
Induced pluripotent stem cell (iPSC)-derived motor neurons (MNs) offer a promising model system for understanding motor neuron diseases (MNDs) and advancing drug discovery. However, variability in differentiation outcomes presents a major barrier to reproducibility and model reliability. This study evaluates a widely adopted small molecule protocol for MN differentiation to quantify variability and identify its sources within an industrial setting. Analysing data from 15 differentiation sets across 8 cell lines, we found that non-genetic factors - particularly induction set and operator - were the predominant sources of variability, outweighing the contribution from cell line genetics. We further demonstrated that iPSC genomic instability, as assessed by a targeted RT-qPCR assay for common karyotypic abnormalities, significantly affected differentiation efficiency and purity. Cultures derived from genomically stable iPSCs exhibited reduced variance and improved MN marker expression profiles. These findings support routine genomic assessment of iPSCs as a practical and effective strategy to enhance the reliability of iPSC-derived MN models, thereby improving their utility in preclinical MND research and therapeutic development.
Overview
CoChat Summary
TL;DR
This study evaluates the widely used Hall et al. small-molecule motor neuron differentiation protocol across 15 induction sets and 8 iPSC lines, finding that non-genetic factors—especially induction set and operator—dominate variability over cell line genetics. Routine RT-qPCR monitoring of common iPSC karyotypic abnormalities is proposed as an accessible way to reduce differentiation variability and improve motor neuron purity.
Key findings
- Most quantitative QC metrics showed high variability: coefficient of variance (CV) was >30% for most metrics, with over half exceeding 40%, far above the ideal <20% for an industrial setting. For example, NPC:D3 CV was 59.5%, D3:D10 CV was 67.0%, and D10 neurite area CV was 53.7%.
- Linear modelling attributed large variation to “Operator” and “Induction Set,” with cell line generally low in magnitude. Operator explained 67.1% of NPC:D3 variation; induction set explained 51.1% of PAX6+OLIG2 (NPC), 57.2% of SMI32+MAP2 (D10), and 45.4% of ISL1+MAP2 (D3) variation. Cell line was significant but usually had R² <12%.
- iPSC genomic instability affected differentiation. Cultures from lines with no detectable chromosomal abnormalities had lower CVs for several purity metrics, including PAX6+OLIG2 (13.57% to 1.81%), SMI32+MAP2 D3 (18.64% to 7.09%), and ISL1+MAP2 D3 (16.25% to 8.33%), and significantly greater purities at NPC and D3 stages (e.g., PAX6+OLIG2 80.83% to 94.25%; SMI32+MAP2 D3 71.17% to 87.25%; ISL1+MAP2 D3 70.67% to 86.75%; p < 0.05).
- Cell lines with confirmed or suspected chromosomal deletions showed morphological abnormalities: confirmed cases had complete lack of motor neuronal organisation, while suspected cases retained some neuronal networks but with dense clusters and rapidly proliferating non-neuronal cells.
Methods
- Data came from 15 differentiation sets across 8 cell lines, with a minimum of 3 induction sets per cell line and per operator. Motor neurons were generated using the Hall et al. small-molecule protocol, with QC assessed at neural precursor cell stage and after 3 or 10 days of terminal differentiation.
- iPSC genomic stability was assessed by a bulk RT-qPCR assay targeting the nine most common karyotypic abnormalities in human iPSCs, with five differentiation rounds across two cell lines. Copy numbers <1.5 or >2.5 (<0.7 or >1.3 for chromosome X in male donors) were considered abnormal, confirmed by one-way ANOVA with post hoc Tukey adjustment.
- Variability analysis used coefficient of variance, linear models in R for quantitative QC metrics, and t-tests, chi-squared tests, and F tests for significance testing.
Limitations
- Stated: variability in motor neuronal purity remains high, and whether it can be reduced further remains a current hurdle. Operator years of cell culture experience showed no significant effect, suggesting unrecorded handling techniques unique to each operator may play a key role.
- Stated: continued monitoring of genomic stability is needed because low-level chromosomal mosaicism has been shown in routine iPSC cultures.
- Evident from the text: the genomic stability assessment used only two cell lines and five differentiation rounds, limiting generalizability; the study also notes that large-scale automated systems shown to reduce variation are not widely available.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
16 Valid · 1 Not valid · 1 Not checked · 23 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, variability in differentiation outcomes presents a major barrier to reproducibility and model reliability.”
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Abstract
What the sources say
- Could not verifycites [11] Yoshihara, M., Hayashizaki, Y. & Murakawa, Y. Genomic instability of iPSCs: challenges towards their clinical applications. Stem cell. Reviews Rep. 13, 7–16 (2017). sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says iPSCs can differentiate into many cell types and be used for disease modeling. The sections on the Origin of Genomic Instability and Concluding Remarks (pages unavailable) discuss genetic variation and clinical safety, but do not address variability in differentiation outcomes as a barrier to reproducibility or model reliability. Searches for differentiation, reproducibility, and variation in differentiation outcomes found no passage making that point. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Current variability defined here (both genetic and non) remains largely in line with values described elsewhere in literature19”
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Conclusion
What the sources say
- Partly supportedcites [19] Volpato, V. & Webber, C. Addressing variability in iPSC-derived models of human disease: guidelines to promote reproducibility. Dis. Models Mech. 13 (1), dmm042317 (2020). sourceExperimental — accuracy not yet measured
The Genetic background section reports literature estimates for genetic contributions to iPSC variability, including 5–46% of variation in cell phenotypes. The Non-genetic variation section reports that laboratory of origin accounted for up to 60% of variation in one study. These provide values for comparison, but this source does not assess whether the citing study’s own values are in line with them; page numbers were unavailable in our copy. (LLM, conf=0.82)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Here, we examine suitability of the widely used Hall et al. small molecule driven protocol for motor neuron differentiation18”
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Introduction
What the sources say
- Supportedcites [18] Hall, C. E. et al. Progressive motor neuron pathology and the role of astrocytes in a human stem cell model of VCP-related ALS. Cell. Rep. 19 (9), 1739–1749 (2017). source
The Results section (“Generation of iPSCs, Spinal Cord MNs, and ACs”) describes Hall et al.’s motor-neuron differentiation method, including small-molecule inhibitors and subsequent patterning to generate motor-neuron precursors. The citation identifies the protocol the citing authors examine; “widely used” is their characterization of it. (LLM, conf=0.90)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Current therapeutic options yield minimal benefit in broad patient populations2–4”
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Introduction
What the sources say
- Supportedcites [2] Hawrot, J., Imhof, S. & Wainger, B. J. Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs. Neurobiol. Dis. 134, 104680 (2020). source
The Introduction states that no cure exists for either sporadic or familial ALS and that existing treatments extend life by only several months. It also notes that edaravone’s approval was based on a relatively restricted subgroup, supporting the claim that benefit across broad patient populations is limited. (LLM, conf=0.91)
- Partly supportedcites [3] Fang, T. et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 17 (5), 416–422 (2018). sourceExperimental — accuracy not yet measured
The Discussion says riluzole’s survival benefit in ALS was seen as small, supporting the limited-benefit part of the claim. The paper does not establish that current therapeutic options generally yield minimal benefit across broad patient populations; its analysis concerns riluzole in a restricted ALS trial population. (LLM, conf=0.84)
- Partly supportedcites [4] Okada, M. et al. Long-term effects of Edaravone on survival of patients with amyotrophic lateral sclerosis. ENeurologicalSci 11, 11–14 (2018). sourceExperimental — accuracy not yet measured
The Introduction says an edaravone trial failed to show significant efficacy in the full ALS study population, while a post-hoc analysis found greater benefit in early-stage patients. That supports limited benefit in a broad population for one treatment, but not the generalization to current therapeutic options. The Discussion also reports improved functional scores and survival in this study's patients, who included both early and advanced stages of ALS. (LLM, conf=0.77)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Interestingly, instability of chromosomes 12,17,18q and 20q all pertained to increased oncogenic activity in cells28–31”
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Discussion > iPSC genomic instability dictates differentiation culture purity and variability
What the sources say
- Partly supportedcites [28] Kraggerud, S. M. et al. Genome profiles of familial/bilateral and sporadic testicular germ cell tumors. Genes Chromosom. Cancer. 34 (2), 168–174 (2002). sourceExperimental — accuracy not yet measured
The Results and Discussion (page not available in our copy) report 12p amplification and suggest a role for 12p genes in tumor-cell survival; the Discussion also says 17q gain likely involves oncogenic proteins. The Results report 18q loss but do not link it to increased oncogenic activity, and no passage supports the claim about 20q. The claim also states these effects more definitively and broadly than the paper does for testicular germ cell tumors. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [29] Bown, N. et al. 17q gain in neuroblastoma predicts adverse clinical outcome. Med. Pediatr. Oncology: Official J. SIOP—International Soc. Pediatr. Oncol. (Societé Int. D’Oncologie Pédiatrique). 36 (1), 14–19 (2001). doi:10.1002/1096-911x(20010101)36:1
- Not checked — no full text of the sourcecites [30] Popat, S. & Houlston, R. S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and highectal cancer prognosis. Eur. J. Cancer. 41 (14), 2060–2070 (2005). source
- Partly supportedcites [31] Nguyen, H. T. & Duong, H. The molecular characteristics of colorectal cancer: implications for diagnosis and therapy. Oncol. Lett. 16 (1), 9–18 (2018). sourceExperimental — accuracy not yet measured
The CIN pathway section reports gains involving 12q and 20q and losses involving 17p and 18q in colorectal cancer, linking chromosomal changes generally to growth and survival advantages. It also reports gains of chromosomes 12 and 17 and loss of 18q in human embryonic stem-cell lines, but identifies a survival advantage specifically for 20q amplification. It does not establish that instability at all four listed locations increases oncogenic activity in cells. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
18 more claims · 5 with their cited sources checked
Create a free account to see all 41 claims and every source verdict.
- It may state two separate claims as one. 15
- Probably not a substantial claim. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Results > Variability is high and more greatly influenced by non-genetic factors
“Further linear modelling suggested that “Operator”, followed by “Induction Set” explained large amounts of variation within each of the QC metrics”
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Discussion
“Variance and statistical analysis show that factors affecting variability in order of largest to smallest contributor were: induction set > operator > cell line.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Results > Variability is high and more greatly influenced by non-genetic factors
“low p-values associated with each (p < 0.05 in all cases)”
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Results > Variability is high and more greatly influenced by non-genetic factors
“| D10 Neurite Area (µm²) | 53.7 | 7.1 | - | - | 0.65 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Results > Variability is high and more greatly influenced by non-genetic factors
“Whilst “Cell Line” was a significant explanatory factor for variation (p < 0.05 in all cases)”
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Results > Variability is high and more greatly influenced by non-genetic factors
“| NPC: D3 | 59.5 | - | - | 67.1 | 0.77 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Results > iPSC genomic stability is a key determinant of differentiation protocol performance and variability
“(B) detected chromosomal copy numbers of Chr1q, Chr18q < 1.5”
§ Examining iPSC derived motor neuron variability and genome stability monitoring as a solution > Results > iPSC genomic stability is a key determinant of differentiation protocol performance and variability
“| WTSli010-A | 1,2 | Chr1q | 1.51 | 0.93 | ~ |”
Citations
Cites
Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E. M., Logroscino, G., Robberecht, W., Shaw, P. J., Simmons, Z., & van den Berg, L. H. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.71 · Cited by 1,414
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505
Self-citationTranscription factor-mediated differentiation of human iPSCs into neurons
Fernandopulle, M. S., Prestil, R., Grunseich, C., Wang, C., Gan, L., & Ward, M. E. (2018) · Current Protocols in Cell Biology · doi:10.1002/cpcb.51 · Cited by 461
Volpato, V., & Webber, C. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.042317 · Cited by 379
Correction: Amyotrophic lateral sclerosis
Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E. M., Logroscino, G., Robberecht, W., Shaw, P. J., Simmons, Z., & van den Berg, L. H. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.85 · Cited by 374
Modeling ALS with motor neurons derived from human induced pluripotent stem cells
Sances, S., Bruijn, L. I., Chandran, S., Eggan, K., Ho, R., Klim, J. R., Livesey, M. R., Lowry, E., Macklis, J. D., Rushton, D., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4273 · Cited by 289
Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications
Yoshihara, M., Hayashizaki, Y., & Murakawa, Y. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9680-6 · Cited by 283
Logroscino, G., Piccininni, M., Marin, B., Nichols, E., Abd-Allah, F., Abdelalim, A., Alahdab, F., Asgedom, S. W., Awasthi, A., Chaiah, Y., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30404-6 · Cited by 272
Fang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30054-1 · Cited by 259
The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review)
Nguyen, H., & Duong, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8679 · Cited by 244
Cited by
Vijayasimha, M., Srikanth, M., & Priya, M. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11070-3
“Stability layer : monitoring drift across passages/ batches using a small set of sensitive markers (including genomic stability when iPSC-derived producer lines are used), recognizing that stability failures can propagate into downstream phenotypes [4, 5].”
Pathophysiology and biomaterials based therapeutic strategies for spinal muscular atrophy
Nasser, A. A., Nasser, R. A., Singh, H., Veettil, R. M., Tuffaha, M., Oueis, E., Pitsalidis, C., Ashraf, S. M., Athamneh, K. N., & Hassan, S. (2026) · In vitro models · doi:10.1007/s44164-026-00123-z
Hua, C., Qu, C., Yang, L., Zhao, W., Zhao, J., Jia, Y., Ma, C., Shang, P., Li, X., Xie, F., et al. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1914941
“Additionally, hiPSC lines exhibit inherent variability in differentiation propensity and response thresholds (Lancaster and Huch, 2019; Gaffey et al., 2025); whether the observed multi-lineage characteristics are generalizable to other cell lines requires further validation.”
Viljoen, S. J., Chaves, J. C. S., Peall, I. W., White, A. R., & Oikari, L. E. (2026) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2026.126168
Metadata
- Authors
- Gaffey, F., McCoull, D., Vaitone, E., Hedges, E., Lovejoy, C., Yao, Z., Wright, P. D., Mead, R. J., & Stebbeds, W.
- Affiliations
- LifeArc (GB)
- University of Sheffield (GB)
- Corresponding author
- Gaffey, Finbar
- ORCID
- Venue
- Scientific Reports
- Published
- 2025-11-12
- Volume
- 15
- Issue
- 1
- Pages
- 39670-39670
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC12612198
- OpenAlex
- W4416149239
- Semantic Scholar
- 1f6aadd645ac436937fc04dad9180d5791be5f44
- Cited by
- 4
- References
- 31
- Citations by year
- 2026: 4
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Keywords
- iPSC-derived motor neurons, motor neuron differentiation, genome stability, karyotype abnormalities, reproducibility, motor neuron disease, differentiation efficiency
- MeSH terms
- Cell Differentiation, Cell Line, Humans, Motor Neurons, Genomic Instability, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Examining iPSC derived motor neuron variability and genome stability monitoring as a solution. https://app.cochat.ai/papers/10.1038/s41598-025-23378-0
- The paper
- Gaffey, F., McCoull, D., Vaitone, E., Hedges, E., Lovejoy, C., Yao, Z., Wright, P. D., Mead, R. J., & Stebbeds, W. (2025). Examining iPSC derived motor neuron variability and genome stability monitoring as a solution. Scientific Reports. https://doi.org/10.1038/s41598-025-23378-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.